New hope for rare lung cancer mutation? daratumumab trial shows promise
NCT ID NCT05807048
First seen Mar 21, 2026 · Last updated May 21, 2026 · Updated 8 times
Summary
This study tested a drug called daratumumab in 8 people with advanced non-small cell lung cancer that has a specific genetic change (STK11/LKB1 mutation). Participants had already tried standard treatments like chemotherapy and immunotherapy. The goal was to see if daratumumab could shrink tumors. The study was small and designed to find early signals of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER WITH STK11/LKB1 MUTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NYU Langone Health
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.